ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALNYLAM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$233.29+1.46 (+0.63%)
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 100.1
- Dividend yield
- –
Alnylam Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $31.22B | $164.85M |
| Enterprise Value | $27.91B | $87.06M |
| PB Ratio | 23.05 | 2.03 |
| P/TBV Ratio | 23.05 | 2.31 |
Income (trailing twelve months)
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Net Income | $733.11M | -$22.46M |
Returns
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 76.8% | -53.1% |
| Return on Assets (ROA) | 14.5% | -41.0% |
Growth
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 53.0% | 2.25% |
| Revenue Growth (5Y CAGR) | 49.8% | 6.42% |
Balance sheet
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.31B | $62.42M |
| Net Cash (Debt) | $3.31B | $15.68M |
| Net Cash Per Share | $24.72 | $0.66 |
| Equity (Book Value) | $1.35B | $48.79M |
| Book Value Per Share | $10.12 | $1.36 |
| Tangible Book Value | $1.35B | $23.06M |
| Working Capital | $3.11B | $75.77M |
Financial position
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.05 | 3.30 |
| Quick Ratio | 2.79 | 2.39 |
Efficiency
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | $293.25K | -$703.34K |
| Employee Count | 2,500 | 74 |
Dividends and yields
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 2.35% | -22.7% |
Shares
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 133,809,000 | 58,179,650 |
| Float | 133,159,000 | 49,173,100 |
| Shares Held by Insiders | 0.49% | 11.6% |
| Shares Held by Institutions | 99.8% | 59.4% |
Scores
| Measure | Alnylam Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 3.53 | -0.24 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | -1.98 | -2.62 |
Calculated by StockData from Alnylam Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.